Glycoconjugate Journal

, Volume 32, Issue 3–4, pp 119–125 | Cite as

Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index

  • Shu Zhang
  • Kai Jiang
  • Qinle Zhang
  • Kun Guo
  • Yinkun LiuEmail author
Original Article


Serum paraoxonase 1 (PON1) is highly fucosylated in hepatocellular carcinoma (HCC) compared with liver cirrhosis (LC). Herein, lectin ELISA using Aleuria aurantia lectin (AAL) was established, which specifically measured optical density (OD) value of serum fucosylated PON1. PON1 protein ELISA was applied simultaneously. ELISA Index (OD value of fucosylated PON1/OD value of protein PON1) was introduced to indicate PON1 fucosylation level on its protein level (Fuc-PON1). ELISA Index in training group (90 LC and 90 HCC) was measured and area under the ROC curve (AUROC) was 0.803 with 80 % of sensitivity and 64.4 % of specificity in distinguishing early HCC from LC. Within training group, AFP HCC (20/90) exhibited better AUROC (0.850), higher sensitivity (90 %) and specificity (75 %) than AFP+ HCC (70/90). An independent testing set (20 LC and 20 HCC) validated the model and 17 HCC patients were successfully predicted. Meanwhile, serum AFP of 43 LC and 43 HCC had an AUROC of 0.760 with sensitivity of 79.1 % and specificity of 53.5 %. Thus, Fuc-PON1 may serve as a glycan biomarker for distinguishing early HCC from LC patients even with low AFP levels.


Fucosylated paraoxonase 1 Hepatocellular carcinoma Aleuria aurantia lectin ELISA Index Glycobiomarker 



The work was financially supported by National Science and Technology Key Projects of China (2011CB910604), China National Key Projects for Infectious Disease (2012ZX10002-009 and 2012ZX10002-012).

Conflict of interest

The authors have declared no conflict of interest.

Compliance with Ethical Standards

The serum specimens were obtained from the First Affiliated Hospital of Guangxi Medical University. This study was approved by the Research Ethics committee of First Affiliated Hospital of Guangxi Medical University and the Institutional Review Board of the National Cancer Center. Informed consent was obtained from each patient.


  1. 1.
    Parkin, D.M., Bray, F., Ferlay, J., Pisani, P.: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74–108 (2005)CrossRefPubMedGoogle Scholar
  2. 2.
    Caturelli, E., Bartolucci, F., Biasini, E., Vigliotti, M.L., Andriulli, A., Siena, D.A., Attino, V., Bisceglia, M.: Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am. J. Gastroenterol. 97(2), 397–405 (2002). doi: 10.1111/j.1572-0241.2002.05477.x CrossRefPubMedGoogle Scholar
  3. 3.
    Colli, A., Fraquelli, M., Casazza, G., Massironi, S., Colucci, A., Conte, D., Duca, P.: Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 101(3), 513–523 (2006). doi: 10.1111/j.1572-0241.2006.00467.x CrossRefPubMedGoogle Scholar
  4. 4.
    Oka, H., Saito, A., Ito, K., Kumada, T., Satomura, S., Kasugai, H., Osaki, Y., Seki, T., Kudo, M., Tanaka, M.: Collaborative Hepato-Oncology Study Group of J: multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J. Gastroenterol. Hepatol. 16(12), 1378–1383 (2001)CrossRefPubMedGoogle Scholar
  5. 5.
    Sato, Y., Nakata, K., Kato, Y., Shima, M., Ishii, N., Koji, T., Taketa, K., Endo, Y., Nagataki, S.: Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N. Engl. J. Med. 328(25), 1802–1806 (1993). doi: 10.1056/NEJM199306243282502 CrossRefPubMedGoogle Scholar
  6. 6.
    Ohtsubo, K., Marth, J.D.: Glycosylation in cellular mechanisms of health and disease. Cell 126(5), 855–867 (2006). doi: 10.1016/j.cell.2006.08.019 CrossRefPubMedGoogle Scholar
  7. 7.
    Dwek, R.A.: Glycobiology: toward understanding the function of sugars. Chem. Rev. 96(2), 683–720 (1996)CrossRefPubMedGoogle Scholar
  8. 8.
    Precourt, L.P., Amre, D., Denis, M.C., Lavoie, J.C., Delvin, E., Seidman, E., Levy, E.: The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 214(1), 20–36 (2011). doi: 10.1016/j.atherosclerosis.2010.08.076 CrossRefPubMedGoogle Scholar
  9. 9.
    Bunkenborg, J., Pilch, B.J., Podtelejnikov, A.V., Wisniewski, J.R.: Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics 4(2), 454–465 (2004). doi: 10.1002/pmic.200300556 CrossRefPubMedGoogle Scholar
  10. 10.
    Chen, R., Jiang, X., Sun, D., Han, G., Wang, F., Ye, M., Wang, L., Zou, H.: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J. Proteome Res. 8(2), 651–661 (2009). doi: 10.1021/pr8008012 CrossRefPubMedGoogle Scholar
  11. 11.
    Liu, T., Qian, W.J., Gritsenko, M.A., Camp 2nd, D.G., Monroe, M.E., Moore, R.J., Smith, R.D.: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J. Proteome Res. 4(6), 2070–2080 (2005). doi: 10.1021/pr0502065 CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Ferre, N., Marsillach, J., Camps, J., Mackness, B., Mackness, M., Riu, F., Blai, C., Tous, M., Joven, J.: Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J. Hepatol. 45(1), 51–59 (2006). doi: 10.1016/j.jhep.2005.12.018 CrossRefPubMedGoogle Scholar
  13. 13.
    Huang, C., Wang, Y.W., Liu, S.D., Ding, G.Y., Liu, W.R., Zhou, J., Kuang, M., Ji, Y., Kondo, T., Fan, J.: Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. J. Proteome Res. 12(4), 1838–1846 (2013). doi: 10.1021/Pr3011815 CrossRefPubMedGoogle Scholar
  14. 14.
    Sun, C., Chen, P., Chen, Q., Sun, L., Kang, X., Qin, X., Liu, Y.: Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Acta. Biochim. Biophys. Sin. (Shanghai) 44(9), 765–773 (2012). doi: 10.1093/abbs/gms055 CrossRefGoogle Scholar
  15. 15.
    Nakano, M., Nakagawa, T., Ito, T., Kitada, T., Hijioka, T., Kasahara, A., Tajiri, M., Wada, Y., Taniguchi, N., Miyoshi, E.: Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int. J. Cancer 122(10), 2301–2309 (2008). doi: 10.1002/ijc.23364 CrossRefPubMedGoogle Scholar
  16. 16.
    Miyoshi, E., Moriwaki, K., Nakagawa, T.: Biological function of fucosylation in cancer biology. J. Biochem. 143(6), 725–729 (2008). doi: 10.1093/jb/mvn011 CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang, S., Shu, H., Luo, K.X., Kang, X.N., Zhang, Y., Lu, H.J., Liu, Y.K.: N-linked glycan changes of serum haptoglobin beta chain in liver disease patients. Mol. BioSyst. 7(5), 1621–1628 (2011). doi: 10.1039/C1mb05020f CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang, S., Jiang, K., Sun, C., Lu, H.J., Liu, Y.K.: Quantitative analysis of site-specific N-glycans on sera haptoglobin beta chain in liver diseases. Acta Biochim. Biophys. Sin 45(12), 1021–1029 (2013). doi: 10.1093/Abbs/Gmt110 CrossRefPubMedGoogle Scholar
  19. 19.
    Okuyama, N., Ide, Y., Nakano, M., Nakagawa, T., Yamanaka, K., Moriwaki, K., Murata, K., Ohigashi, H., Yokoyama, S., Eguchi, H., Ishikawa, O., Ito, T., Kato, M., Kasahara, A., Kawano, S., Gu, J.G., Miyoshi, E.: Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for Fucosylation. Int. J. Cancer 118(11), 2803–2808 (2006). doi: 10.1002/Ijc.21728 CrossRefPubMedGoogle Scholar
  20. 20.
    Matsumura, K., Higashida, K., Ishida, H., Hata, Y., Yamamoto, K., Shigeta, M., Mizuno-Horikawa, Y., Wang, X.C., Miyoshi, E., Gu, J.G., Taniguchi, N.: Carbohydrate binding specificity of a fucose-specific lectin from aspergillus oryzae - A novel probe for core fucose. J. Biol. Chem. 282(21), 15700–15708 (2007). doi: 10.1074/jbc.M701195200 CrossRefPubMedGoogle Scholar
  21. 21.
    Ahn, J.M., Sung, H.J., Yoon, Y.H., Kim, B.G., Yang, W.S., Lee, C., Park, H.M., Kim, B.J., Kim, B.G., Lee, S.Y., An, H.J., Cho, J.Y.: Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol. Cell. Proteomics 13(1), 30–48 (2014). doi: 10.1074/mcp.M113.028621 CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Matsumoto, H., Shinzaki, S., Narisada, M., Kawamoto, S., Kuwamoto, K., Moriwaki, K., Kanke, F., Satomura, S., Kumada, T., Miyoshi, E.: Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin. Chem. Lab. Med. 48(4), 505–512 (2010). doi: 10.1515/CCLM.2010.095 CrossRefPubMedGoogle Scholar
  23. 23.
    Wu, J., Xie, X., Liu, Y., He, J., Benitez, R., Buckanovich, R.J., Lubman, D.M.: Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. J. Proteome Res. 11(9), 4541–4552 (2012). doi: 10.1021/pr300330z CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Shu Zhang
    • 1
  • Kai Jiang
    • 2
  • Qinle Zhang
    • 2
  • Kun Guo
    • 1
  • Yinkun Liu
    • 1
    • 2
    Email author
  1. 1.Liver Cancer Institute, Zhongshan HospitalKey Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of EducationShanghaiPeople’s Republic of China
  2. 2.Institutes of Biomedical SciencesFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations